RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00034916.xml
PDF herunterladen
Nervenheilkunde 2007; 26(10): 923-927
DOI: 10.1055/s-0038-1626946
DOI: 10.1055/s-0038-1626946
Neuroethik & Neurophilosophie
Neuromodulatorische Interventionen zur Therapie psychiatrischer Erkrankungen
Empirische Perspektiven und ethische ImplikationenAuthors
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
19. Januar 2018 (online)
-
Literatur
- 1 Kessler R, McGonagle K, Zhao S, Nelson C, Hughes M, Eshleman S, Wittchen H, Kendler K. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives Of General Psychiatry 1994; 51 (01) 8-19.
- 2 Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global burden of disease study. The Lancet 1997; 349: 1436-1442.
- 3 Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Mental disorders and cause-specific mortality. Br J Psychiatry 2001; 179: 498-502.
- 4 Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry 1998; 155 (01) 4-11.
- 5 Wulsin LR, Vaillant GE, Wells VE. A systematic review of the mortality of depression. Psychosom Med 1999; 61 (01) 6-17.
- 6 Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ, Graham D, Tsankova NM, Bolanos CA, Rios M, Monteggia LM, Self DW, Nestler EJ. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006; 311 (5762): 864-868.
- 7 Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 07 (02) 137-151.
- 8 Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, Yacoubi ME, Vaugeois JM, Nomikos GG, Greengard P. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 2006; 311 (5757): 77-80.
- 9 Wong ML, Licinio J. Research and treatment approaches to depression. Nat Rev Neurosci 2001; 02 (05) 343-351.
- 10 Keller MB, Lavori PW, Mueller TI, Endicott J, Coryell W, Hirschfeld RM, Shea T. Time to recovery, chronicity, and levels of psychopathology in major depression.A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992; 49 (10) 809-816.
- 11 Nemeroff C. Augmentation strategies in patients with refractory depression. Depress Anxiety 1996; 04: 169-181.
- 12 Mann JJ. The medical management of depression. N Engl J Med 2005; 353 (17) 1819-1834.
- 13 Mayberg H. Modulating dysfunctional limbiccortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. British Medical Bulletin 2003; 65: 193-207.
- 14 Mayberg HS. Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry Clin Neurosci 1997; 09 (03) 471-481.
- 15 Mayberg HS. Positron emission tomography imaging in depression:a neural systems perspective. Neuroimaging Clin NAm 2003; 13 (04) 805-815.
- 16 Mayberg HS. Modulating dysfunctional limbiccortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 2003; 65: 193-207.
- 17 Drevets WC. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res 2000; 126: 413-431.
- 18 Drevets WC. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Current Opinion in Neurobiology 2001; 11 (02) 240-249.
- 19 Schlaepfer TE, Lieb K. Deep Brain Stimulation for Treatment Refractory Depression. Lancet 2005; 366 (9495): 1420-1422.
- 20 Deuschl G, Bain P. Deep brain stimulation for tremor: patient selection and evaluation. Mov Disord 2002; 17 Suppl 3: S102-111.
- 21 Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K, Daniels C, Deutschlander A, Dillmann U, Eisner W, Gruber D, Hamel W, Herzog J, Hilker R, Klebe S, Kloss M, Koy J, Krause M, Kupsch A, Lorenz D, Lorenzl S, Mehdorn HM, Moringlane JR, Oertel W, Pinsker MO, Reichmann H, Reuss A, Schneider GH, Schnitzler A, Steude U, Sturm V, Timmermann L, Tronnier V, Trottenberg T, Wojtecki L, Wolf E, Poewe W, Voges J. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 2006; 355 (09) 896-908.
- 22 Nuttin B, Gybels J, Cosyns P, Gabriels L, Meyerson B, Andréewitch S, Rasmussen S, Greenberg B, Friehs G, Rezai AR, Montgomery E, Malone D, Fins JJ. Deep Brain Stimulation for Psychiatric Disorders. Neurosurgery 2002; 51 (02) 519.
- 23 Greenberg BD, Malone DA, Friehs GM, Rezai AR, Kubu CS, Malloy PF, Salloway SP, Okun MS, Goodman WK, Rasmussen SA. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology 2006; 31 (11) 2394.
- 24 Mayberg H, Lozano A, Voon V, McNeely H, Seminowicz D, Hamani C, Schwalb J, Kennedy S. Deep brain stimulation for treatment-resistant depression. Neuron 2005; 45 (05) 651-660.
- 25 Schlaepfer TE, Cohen MX, Frick C, Kosel M, Brodesser D, Axmacher N, Joe AJ, Kreft M, Lenartz D, Sturm V. Deep Brain Stimulation to Reward Circuitry Alleviates Anhedonia in Refractory Major Depression. Neuropsychopharmacology. 2007 doi:10.1038/sj.npp.1301408.
- 26 Beric A, Kelly PJ, Rezai A, Sterio D, Mogilner A, Zonenshayn M, Kopell B. Complications of deep brain stimulation surgery. Stereotact Funct Neurosurg 2001; 77 (1–4): 73-78.
- 27 Fins JJ, Rezai AR, Greenberg BD. Psychosurgery: avoiding an ethical redux while advancing a therapeutic future. Neurosurgery 2006; 59 (04) 713-716.
- 28 Farah MJ. Emerging ethical issues in neuroscience. Nat Neurosci 2002; 05 (11) 1123-1129.
- 29 Farah MJ, Illes J, Cook-Deegan R, Gardner H, Kandel E, King P, Parens E, Sahakian B, Wolpe PR. Neurocognitive enhancement: what can we do and what should we do?. Nat Rev Neurosci 2004; 05 (05) 421-425.